Meropenem Panpharma Infusion
Meropenem
1g
PANPHARMA
| Pack size | 10 Glass Vials |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | PHARMALINK |
| Retail Price | 500.50 AED |
Indications
Meropenem Panpharma Infusion is used for:
Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection
Adult Dose
Intravenous
Intra-abdominal infections
Adult: 1 g 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
Skin and skin structure infections
Adult: 500 mg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
Cystic fibrosis, Meningitis
Adult: 2 g 8 hrly infused over approx 15-30 min.
Susceptible infections
Adult: 0.5-1 g 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
Hepatic impairment: No dosage adjustment needed.
Child Dose
Children:
IV 60 mg/kg/day, max 3 g/day q8h
120 mg/kg/day meningitis, max 6 g/day q8h
Intravenous
Intra-abdominal infections
Child: >3mth ?50 kg: 20 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 1000 mg.
Skin and skin structure infections
Child: >3 mth ?50 kg: 10 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 500 mg.
Cystic fibrosis, Meningitis
Child: >3 mth ?50 kg: 40 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min. Max: 2 g.
Susceptible infections
Child: >3 mth ?50 kg: 10 or 20 mg/kg 8 hrly via IV inj over approx 3-5 min or infused over approx 15-30 min.
Renal Dose
Renal impairment:
CrCl (ml/min)
26-50 Usual dose 12 hrly.
10-25 Half the usual dose 12 hrly.
<10 Half the usual dose 24 hrly.
Administration
IV Administration
Administer IV infusion over 15-30 minutes; administer IV bolus over 3-5 minutes
Contra Indications
Hypersensitivity to meropenem, other carbapenems. History of anaphylactic reaction to β-lactams (e.g. penicillins, cephalosporins).
Precautions
Patient w/ underlying CNS disorders (e.g. brain lesions, history of seizures. Not recommended for treatment of MRSA. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor for signs of anaphylaxis during 1st dose. Periodically assess renal, hepatic, and haematopoietic functions during prolonged therapy.
Lactation: Unknown whether drug is excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy
There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women
Animal data
No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively; in rats administered intravenous meropenem in late pregnancy and during lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison
Lactation
Drug has been reported to be excreted in human milk; no information is available on effects of drug on breast-fed child or on milk production; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breast-fed child from therapy or from the underlying maternal condition
Interactions
Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
Adverse Effects
Side effects of Meropenem :
1-10%
Constipation (1-7%), Diarrhea (4-5%), Nausea or vomiting (1-4%), Rash (2-3%; includes diaper-area moniliasis in pediatric patients), Headache (2%), Inflammation at injection site (2%), Sepsis (2%), Oral moniliasis (≤2% in pediatric patients), Bleeding (1.2%), Apnea (1%), Constipation (1%), Glossitis (1%), Injection-site reaction (1%), Phlebitis or thrombophlebitis (1%), Pruritus (1%), Septic shock (1%)
<1%
Agranulocytosis, Angioedema, Erythema multiforme, Hypersensitivity reaction, Hypokalemia, Leukopenia, Neutropenia, Pleural effusion, Stevens-Johnson syndrome, Toxic epidermal necrolysis disorders or renal impairment.
Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
Mechanism of Action
Meropenem is a synthetic carbapenem beta-lactam antibiotic that exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in gm+ve and gm-ve bacteria through binding to several penicillin-binding proteins (PBPs).
Note
Meropenem Panpharma 1g Infusion manufactured by PANPHARMA. Its generic name is Meropenem. Meropenem Panpharma is availble in United Arab Emirates.
Farmaco UAE drug index information on Meropenem Panpharma Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.